Clinical Trials Sponsored by NeoTherapeutics

Total 396 results

Atara Biotherapeutics

Recruiting

A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

High-grade B-cell Lymphoma | MCL | Diffuse Large B-cell Lymphoma (DLBCL) | Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | DLBCL/High-grade B-cell Lymphoma With MYC and BCL2 Rearrangements | Anaplastic Lymphoma Kinase-Positive Large B-Cell Lymphoma | LBCL With IRF4 Rearrangement | High-grade B-cell... and other conditions

United States
Alethia Biotherapeutics

Recruiting

Sotevtamab (AB-16B5) Combined With FOLFOX as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis (EGIA-003)

Metastatic Colorectal Cancer

Canada
Tavotek Biotherapeutics

Recruiting

A Study of TAVO101 in Atopic Dermatitis Patients

Atopic Dermatitis

New Zealand
Aro Biotherapeutics

Recruiting

Study to Assess the Safety, Tolerability, PK and PD of ABX1100

Healthy

Canada
Latigo Biotherapeutics

Recruiting

A Phase 1 Single and Multiple Ascending Dose Study of LTG-001 Administered Orally in Healthy Participants

Healthy

New Zealand
Barinthus Biotherapeutics

Completed

Prime-boost Vaccine Study in Women With Low-grade Cervical HPV Lesions

HPV Infection | CIN1

Belgium, United Kingdom, Estonia
Oncotherapeutics
Takeda

Terminated

Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients

Newly Diagnosed Multiple Myeloma

United States
BrightPath Biotherapeutics

Terminated

GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC

Metastatic NSCLC

United States
Northwest Biotherapeutics

Active, not recruiting

Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer (GBM)

Glioma | Glioblastoma | Brain Cancer | Brain Tumor | Glioblastoma Multiforme | GBM | Grade IV Astrocytoma

United States, Germany, Canada, United Kingdom
Aeglea Biotherapeutics

Completed

A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors

Advanced Cancers

United States
Alethia Biotherapeutics

Completed

Phase I Dose Escalation Study of AB-16B5 in Subjects With an Advanced Solid Malignancy

Solid Tumor | Metastatic Cancer

Canada
Eleven Biotherapeutics

Completed

Phase 3 Study of EBI-005 in Dry Eye Disease (EBI-005)

Dry Eye Disease (DED)

United States
Eleven Biotherapeutics

Completed

A Single Center Study for the Treatment of Moderate to Severe Allergic Conjunctivitis (EBI-005-AC-1)

Allergic Conjunctivitis

Canada
Oncotherapeutics
Novartis

Completed

Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma

Multiple Myeloma

United States
Eleven Biotherapeutics

Completed

A Multi-Center Study Subjects With Dry Eye Syndrome (EBI)

Dry Eye Syndrome

United States
Eleven Biotherapeutics

Completed

Phase 1 Study for Safety and Tolerability of EBI-005 Topically Administered to Eyes of Healthy Adult Subjects (EBI-005-1)

Dry Eye

United States
Northwest Biotherapeutics

Withdrawn

Study of a Drug [DCVax (tm)-Prostate] to Treat Prostate Cancer When Hormone Therapy is no Longer Effective.

Prostate Cancer

United States
Jennerex Biotherapeutics

Terminated

Neoadjuvant Study of Recombinant Vaccinia Virus to Treat Metastatic Colorectal Carcinoma in Patients Undergoing Complete Resection of Liver Tumors

Colorectal Carcinoma

Canada
GMP Endotherapeutics

Completed

Single Dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient Patients

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1

United States
Claris Biotherapeutics, Inc.

Recruiting

Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Corneal Scars

Corneal Scar

United States
Auregen Biotherapeutics, SA

Recruiting

Long-Term Follow-Up Study of Unilateral Microtia Patients Implanted With AUR-201 (AUR-201)

Microtia

United States
Auregen Biotherapeutics, SA

Recruiting

Subcutaneous Implant Combination Product (AUR-201) in Patients With Unilateral Microtia (AUR-201)

Microtia

United States
Bridge Biotherapeutics, Inc.

Recruiting

First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI

EGFR Mutant Advanced Non-Small Cell Lung Cancer

Korea, Republic of, United States
NovaRock Biotherapeutics, Ltd

Recruiting

A Study of NBL-020 Injection in Subjects With Advanced Malignant Tumors.

Advanced Malignant Tumors

China
Immorna Biotherapeutics, Inc.

Recruiting

Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors

Malignant Solid Tumor | Cutaneous Tumor

China
Salubris Biotherapeutics Inc

Recruiting

Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer

Melanoma | Clear Cell Renal Cell Carcinoma | Cancer | Hepatocellular Carcinoma | Colorectal Cancer | Pancreatic Adenocarcinoma | Gastric Adenocarcinoma | Metastatic Cancer | Squamous Cell Carcinoma of Head and Neck | Triple Negative Breast Cancer | Advanced Solid Tumor | Epithelial Ovarian Cancer | Non-small Cell... and other conditions

Belgium, Spain
TILT Biotherapeutics Ltd.

Recruiting

TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 Monotherapy (TUNIMO)

Solid Tumor

Finland
Iovance Biotherapeutics, Inc.

Recruiting

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

Metastatic Non Small Cell Lung Cancer

United States, Canada, Germany, Netherlands, Switzerland
Oxford BioTherapeutics Ltd

Recruiting

Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors

Solid Tumor

United States, Belgium, Spain, France, Greece
Iovance Biotherapeutics, Inc.

Recruiting

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

Squamous Cell Carcinoma of the Head and Neck | Metastatic Melanoma | Non-small Cell Lung Cancer

United States, Spain, Canada, France, Germany, Greece, Switzerland, United Kingdom
Stealth BioTherapeutics Inc.

Completed

A Trial to Evaluate Safety, Tolerability and Efficacy of Elamipretide in Subjects With Barth Syndrome (TAZPOWER)

Barth Syndrome

United States
Arcutis Biotherapeutics, Inc.

Completed

Safety and Efficacy of ARQ-252 Cream in Subjects With Chronic Hand Eczema

Chronic Hand Eczema

United States, Australia, Canada
TILT Biotherapeutics Ltd.

Active, not recruiting

TNFalpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 During TIL Treatment of Advanced Melanoma (TUNINTIL)

Metastatic Melanoma

France, Denmark
Auregen Biotherapeutics, SA

Enrolling by invitation

Subcutaneous Implant Combination Product (AUR-201) in Patients With Unilateral Microtia (Australia) (AUR-201)

Microtia

Australia
Arcutis Biotherapeutics, Inc.

Active, not recruiting

Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-OLE)

Atopic Dermatitis Eczema

United States, Canada
Oncotherapeutics
Celgene Corporation

Terminated

Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients

Multiple Myeloma

United States
Conjupro Biotherapeutics, Inc.

Suspended

Dose Escalation and Expansion Study of CPO107 for Patients With Advanced CD20-positive Non-Hodgkins Lymphoma

CD20 Positive Non Hodgkin Lymphoma

United States
Stealth BioTherapeutics Inc.

Completed

ReCLAIM-2 Study to Evaluate Safety,Efficacy & Pharmacokinetics of Elamipretide in Subjects With AMD With Non-central GA (ReCLAIM-2)

Age-related Macular Degeneration

United States
Iovance Biotherapeutics, Inc.

No longer available

Expanded Access Program of Lifileucel (LN-144) in Patients With Unresectable or Metastatic Melanoma

Metastatic Melanoma | Unresectable Melanoma

United States
Arcutis Biotherapeutics, Inc.

Completed

Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-II)

Atopic Dermatitis Eczema

United States, Canada
Salubris Biotherapeutics Inc

Withdrawn

Single-Ascending Dose Study of JK07 in Subjects With HFpEF

Heart Failure With Preserved Ejection Fraction

United States
REMD Biotherapeutics, Inc.

Completed

Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus

Type1 Diabetes Mellitus

United States
Immorna Biotherapeutics, Inc.

Active, not recruiting

Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors

Malignant Solid Tumor | Cutaneous Tumor

United States
1ST Biotherapeutics, Inc.

Completed

Safety, Tolerability, and Pharmacokinetics of Oral FB-101 in Healthy Subjects

Parkinson's Disease

United States
Arcutis Biotherapeutics, Inc.

Completed

Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis (DERMIS-2)

Chronic Plaque Psoriasis

United States, Canada
Arcutis Biotherapeutics, Inc.

Completed

Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body Psoriasis

Plaque Psoriasis

United States, Australia, Bulgaria, Canada
Arcutis Biotherapeutics, Inc.

Terminated

Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial Vitiligo

Vitiligo

United States
Centus Biotherapeutics Limited

Completed

Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer (AVANA)

Carcinoma, Non-Small-Cell Lung

United States, Belarus, Bosnia and Herzegovina, Bulgaria, Croatia, Georgia, Germany, Greece, Hungary, Italy, Japan, Korea, Republic of, Peru, Philippines, Poland, Romania, Russian Federation, Serbia, Spain, Taiwan, Thailand, Turkey, Ukrain... and more
Stealth BioTherapeutics Inc.

Completed

A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for Treatment of Leber's Hereditary Optic Neuropathy

Leber's Hereditary Optic Neuropathy

United States
Stealth BioTherapeutics Inc.

Completed

A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for the Treatment of Fuchs' Corneal Endothelial Dystrophy (FCED) (SPIFD-101)

Fuchs' Corneal Endothelial Dystrophy (FCED)

United States

Clinical Trials Sponsored by NeoTherapeutics

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malta

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations